This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management
by Zacks Equity Research
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Avantor, Inc. (AVTR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.57% and 0.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 27.45% and 1.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up
by Zacks Equity Research
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.
Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.
Avantor, Inc. (AVTR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 6.67% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Premier, Inc. (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 0.58% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avantor (AVTR) Q3 Earnings Top Estimates, 2022 EPS View Cut
by Zacks Equity Research
Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.
Avantor, Inc. (AVTR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.03% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Premier, Inc. (PINC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Premier, Inc. (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Avantor, Inc. (AVTR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Avantor (AVTR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Avantor (AVTR) stock based on the movements in the options market lately.
U.S. Market Faces Worst Meltdown Since 2020: Here's Why
by Indrajit Bandyopadhyay
Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.
Implied Volatility Surging for Avantor (AVTR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Avantor (AVTR) stock based on the movements in the options market lately.
Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss
by Zacks Equity Research
Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.
Avantor, Inc. (AVTR) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -2.63% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AVTR or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AVTR vs. DOCS: Which Stock Is the Better Value Option?
Factors that Make Acadia Healthcare (ACHC) an Attractive Bet Now
by Zacks Equity Research
Solid demand for behavioral healthcare services, growth-related efforts in the form of JVs, declining debt burden and sufficient cash-generating abilities continue to benefit Acadia Healthcare (ACHC).
AVTR vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AVTR vs. DOCS: Which Stock Is the Better Value Option?
The Beauty Health Company (SKIN) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.